Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multinational, open-label, non-controlled trial on safety, efficacy and pharmacokinetics of NNC 0129-0000-1003 in previously treated paediatric patients with severe haemophilia A

Trial Profile

A multinational, open-label, non-controlled trial on safety, efficacy and pharmacokinetics of NNC 0129-0000-1003 in previously treated paediatric patients with severe haemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Turoctocog alfa pegol (Primary)
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Acronyms PATHFINDER 5
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Jan 2022 Results of post-hoc analysis of two studies (pathfinder 2 and pathfinder 5) assessing long-term efficacy and pharmacokinetic outcomes with fixed-dose N8-GP prophylaxis, published in the Haemophilia.
    • 01 Sep 2020 End-of-trial safety and efficacy results of the combined main and extension phases published in the Journal of Thrombosis and Haemostasis
    • 09 Mar 2020 Results of NCT01731600 and NCT01480180 assesing plasma polyethylene glycol concentrations, repeatedly treated with N8-GP for periods of up to 5 years, published in the Drugs in R and D.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top